A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on ...

Please provide your email address to receive an email when new articles are posted on . A new model showed greater accuracy at predicting prostate cancer mortality vs. existing tools. It incorporates ...

Researchers at Norwegian University of Science and Technology are developing an artificial intelligence tool to detect prostate cancer. Early trials show promising results, suggesting faster, more ...

PANAMA CITY, Fla. (WJHG/WECP) - Hope Regional Medical Center in Panama City is now using a powerful new diagnostic tool in the fight against Prostate Cancer. Doctors at the center have always used CT ...

Digital Health News: Daniel Spratt, chair of radiation oncology at Case Comprehensive Cancer Center, commented on a new AI-enabled prostate cancer risk assessment tool has been developed to analyze ...

Early detection of recurrent prostate cancer using 18F-DCFPyL PET/CT PET/CT in patients with minimal PSA levels. Patient, companion, and physician survey questions and results.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.